(Reuters) – The U.S. health regulator on Friday approved Regeneron Pharmaceuticals’ drug to treat a rare blood disease, the company said.
The drug, Veopoz, is the first treatment to be approved by the U.S. Food and Drug Administration (FDA) for patients suffering from the life-threatening CHAPLE disease.
(Reporting by Vaibhav Sadhamta and Khushi Mandowara in Bengaluru; Editing by Shilpi Majumdar)
